Sanggenol FCAS# 202526-51-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 202526-51-0 | SDF | Download SDF |
PubChem ID | 77137009 | Appearance | Powder |
Formula | C25H26O7 | M.Wt | 438.5 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 1,3,8,10a-tetrahydroxy-2,5a-bis(3-methylbut-2-enyl)-[1]benzofuro[3,2-b]chromen-11-one | ||
SMILES | CC(=CCC1=C(C2=C(C=C1O)OC3(C4=C(C=C(C=C4)O)OC3(C2=O)O)CC=C(C)C)O)C | ||
Standard InChIKey | KDTSLDXCGUETMJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C25H26O7/c1-13(2)5-7-16-18(27)12-20-21(22(16)28)23(29)25(30)24(31-20,10-9-14(3)4)17-8-6-15(26)11-19(17)32-25/h5-6,8-9,11-12,26-28,30H,7,10H2,1-4H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Sanggenol F Dilution Calculator
Sanggenol F Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2805 mL | 11.4025 mL | 22.805 mL | 45.61 mL | 57.0125 mL |
5 mM | 0.4561 mL | 2.2805 mL | 4.561 mL | 9.122 mL | 11.4025 mL |
10 mM | 0.2281 mL | 1.1403 mL | 2.2805 mL | 4.561 mL | 5.7013 mL |
50 mM | 0.0456 mL | 0.2281 mL | 0.4561 mL | 0.9122 mL | 1.1403 mL |
100 mM | 0.0228 mL | 0.114 mL | 0.2281 mL | 0.4561 mL | 0.5701 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Moracin B
Catalog No.:BCX0468
CAS No.:67259-16-9
- Procumboside A
Catalog No.:BCX0467
CAS No.:850894-16-5
- Zataroside A
Catalog No.:BCX0466
CAS No.:95645-53-7
- 6β-Hydroxy-7-epi-α-cyperone
Catalog No.:BCX0465
CAS No.:6851-55-4
- Alpinenone
Catalog No.:BCX0464
CAS No.:103425-23-6
- 15-O-Ethylzerumin B
Catalog No.:BCX0463
CAS No.:1707019-00-8
- Monardin C
Catalog No.:BCX0462
CAS No.:1262796-93-9
- (E)-14-Hydroxy-15-norlabda-8(17),12-dien-16-al
Catalog No.:BCX0461
CAS No.:114370-19-3
- 6'-O-Glucopyranosylalbiflorin
Catalog No.:BCX0460
CAS No.:1001644-88-7
- Breynioside A
Catalog No.:BCX0459
CAS No.:63555-02-2
- Sanggenon M
Catalog No.:BCX0458
CAS No.:922080-11-0
- Sanggenon A
Catalog No.:BCX0457
CAS No.:76464-71-6
- 15-Hydroxylabda-8(17),12E-dien-16-al
Catalog No.:BCX0470
CAS No.:283614-59-5
- 6'-O-p-Hydroxybenzoylgastrodin
Catalog No.:BCX0471
CAS No.:1551525-70-2
- Mulberrofuran V
Catalog No.:BCX0472
CAS No.:174423-49-5
- Labda-8(17),12E,14-trien-16,15-olide
Catalog No.:BCX0473
CAS No.:917078-10-5
- Galanal B
Catalog No.:BCX0474
CAS No.:104113-52-2
- Methyl indole-3-acetate
Catalog No.:BCX0475
CAS No.:1912-33-0
- Rankinidine
Catalog No.:BCX0476
CAS No.:106466-66-4
- Sinapyl alcohol
Catalog No.:BCX0477
CAS No.:537-33-7
- Gypenoside LXXV
Catalog No.:BCX0478
CAS No.:110261-98-8
- Indole-3-acetic acid β-D-glucopyranosyl ester
Catalog No.:BCX0479
CAS No.:19817-95-9
- Schisanhenol B
Catalog No.:BCX0480
CAS No.:102681-52-7
- Schisandrathera D
Catalog No.:BCX0481
CAS No.:2694046-04-1
Isoprenylated flavonoids from Morus nigra and their PPAR gamma agonistic activities.[Pubmed:29427594]
Fitoterapia. 2018 Jun;127:109-114.
A novel dihydroflavonol unprecedentedly with a prenyl group at C-2, nigragenon A (1), four new sanggenon-type flavonones, nigragenons B-E (2-5), along with six known isoprenylated flavonoids (6-11) were isolated from the twigs of Morus nigra. Their structures were elucidated through extensive analysis of spectroscopic data. Interestingly, compound 1 was the first reported biogenetic precursor of sanggenon-type flavanones and the biogenetic pathway from 1 to Sanggenol F was proposed. The PPAR gamma agonistic activity was investigated in HEK293 cells using dual luciferase reporter assay. Compounds 2, 4, 7, and 9 showed obvious agonistic activities on PPAR gamma, and compound 2 was a potential PPAR gamma partial agonist. Moreover, the preliminary structure-activity relationships for the tested compounds were discussed.
Sanggenol F exerts anti-diabetic effects via promoting adipocyte differentiation and modifying adipokines expression.[Pubmed:28004237]
Endocrine. 2017 Apr;56(1):73-81.
Adipose tissue is not only a lipid storage site, but also a well-known endocrine organ. Dysfunction of adipose tissue is associated with irregular lipid metabolism, ectopic lipid accumulation and insulin resistance. It is proposed that modulating on adipose tissue is a reasonable way to ameliorate glucose and lipid metabolism. (+/-)-Sanggenol F (SGF, purity >98.5%) was synthesized as a racemic mixture of natural (+)-Sanggenol F. In this study, SGF was found to promote adipocyte differentiation, enhance insulin sensitivity, and upregulate beneficial adipokines expression in 3T3-L1 cells. Furthermore, in vivo study showed that treatment with SGF for 4 weeks improved glucose metabolism, by decreasing fasting blood glucose and enhancing insulin sensitivity. It also improved lipid metabolism, with reduced serum lipid level and ameliorated hepatic steatosis in db/db mice. During the process of target finding, we found that SGF had multiple activities of protein tyrosine phosphatase 1B inhibition, peroxisome proliferator-activated receptor gamma and peroxisome proliferator-activated receptor alpha agonism. These results showed the potential of SGF as a candidate for the therapy of type 2 diabetes.
Asymmetric Syntheses of the Flavonoid Diels-Alder Natural Products Sanggenons C and O.[Pubmed:26735066]
J Am Chem Soc. 2016 Jan 27;138(3):798-801.
Metal-catalyzed, double Claisen rearrangement of a bis-allyloxyflavone has been utilized to enable a concise synthesis of the hydrobenzofuro[3,2-b]chromenone core structure of the natural products sanggenon A and Sanggenol F. In addition, catalytic, enantioselective [4+2] cycloadditions of 2'-hydroxychalcones have been accomplished using B(OPh)3/BINOL complexes. Asymmetric syntheses of the flavonoid Diels-Alder natural products sanggenons C and O have been achieved employing a stereodivergent reaction of a racemic mixture (stereodivergent RRM) involving [4+2] cycloaddition.